KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Quest Diagnostics (DGX) EBIAT (2016 - 2026)

Quest Diagnostics' EBIAT history spans 18 years, with the latest figure at $264.0 million for Q1 2026.

  • On a quarterly basis, EBIAT rose 12.34% to $264.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.1 billion, a 13.46% increase, with the full-year FY2025 number at $1.0 billion, up 13.57% from a year prior.
  • EBIAT hit $264.0 million in Q1 2026 for Quest Diagnostics, down from $299.0 million in the prior quarter.
  • Over the last five years, EBIAT for DGX hit a ceiling of $373.0 million in Q1 2022 and a floor of $101.0 million in Q4 2022.
  • Historically, EBIAT has averaged $241.8 million across 5 years, with a median of $240.0 million in 2024.
  • Biggest five-year swings in EBIAT: crashed 69.21% in 2022 and later soared 80.13% in 2024.
  • Tracing DGX's EBIAT over 5 years: stood at $101.0 million in 2022, then soared by 49.5% to $151.0 million in 2023, then surged by 80.13% to $272.0 million in 2024, then increased by 9.93% to $299.0 million in 2025, then fell by 11.71% to $264.0 million in 2026.
  • Business Quant data shows EBIAT for DGX at $264.0 million in Q1 2026, $299.0 million in Q4 2025, and $259.0 million in Q3 2025.